Home Page Overall Ranking ROE Ranking P/E Ranking Dividend Yield Capitalization Our eBook Our Book Contact










Isin US00287Y1091
Ticker ABBV
Company ABBVIE
Currency $
Price
Aware Investor Index (AII) 273.3097
Recommendation STRONG BUY
P/E 31.25
ROE 86.11 %
Capitalization 137,136,650,000 $
Dividend Yield 3.07 %
P/S 4.86
AII Position 22
P/E Position 470
ROE Position 38
Capitalization Position 53
Dividend Yield Position 238
Sales 28,216,000,000 $
10-Year Average Earnings 4,388,800,000 $
Shares Outstanding 1,603,000,000
Equity 5,097,000,000 $
Dividend per Share 2.63 $
Industry Pharmaceutical
Country United States
ABBVIE Investor Relations Web Site http://www.abbvieinvestor.com







Sales:

YEAR MONTH AMOUNT
2017 12 28,216,000,000.00 $
2016 12 25,638,000,000.00 $
2015 12 22,859,000,000.00 $
2014 12 19,960,000,000.00 $
2013 12 18,790,000,000.00 $
2012 12 18,380,000,000.00 $
2011 12 17,444,000,000.00 $
2010 12 15,638,000,000.00 $
2009 12 14,214,000,000.00 $
2008 12 14,179,000,000.00 $

Earnings:

YEAR MONTH AMOUNT
2017 12 5,309,000,000.00 $
2016 12 5,953,000,000.00 $
2015 12 5,144,000,000.00 $
2014 12 1,774,000,000.00 $
2013 12 4,128,000,000.00 $
2012 12 5,275,000,000.00 $
2011 12 3,433,000,000.00 $
2010 12 4,178,000,000.00 $
2009 12 4,636,000,000.00 $
2008 12 4,058,000,000.00 $

Equity:

YEAR MONTH AMOUNT
2017 12 5,097,000,000.00 $
2016 12 4,636,000,000.00 $
2015 12 3,945,000,000.00 $
2014 12 1,742,000,000.00 $
2013 12 4,492,000,000.00 $
2012 12 3,363,000,000.00 $

Shares Outstanding:

YEAR MONTH AMOUNT
2017 12 1,603,000,000
2016 12 1,631,000,000
2015 12 1,637,000,000
2014 12 1,610,000,000
2013 12 1,604,000,000
2012 12 1,577,000,000

 












Bloomberg News for ABBVIE:



Google News for ABBVIE:

Seeking Alpha - 2 days ago
Why AbbVie Believes In Life After (Humira's) Death
ABBV has been mired in a bear market, in large part due to worse-than-expected competition to Humira from biosimilars in the EU.
Seeking Alpha - 3 days ago
Rep. Cummings opens investigation into drug prices
The targeted companies are: AbbVie (ABBV -2.6%), Amgen (AMGN -1.7%), AstraZeneca (AZN -3.7%), Celgene (CELG -0.1%), Eli Lilly (LLY ...
Seeking Alpha - 10 Jan 2019
AbbVie - Stemcentrx Impairment, A Worrying Sign?
AbbVie (ABBV) had some bad news to share with investors at the start of the year although much of this has already been priced in.
Fairfield Current - 9 hours ago
$8.38 Billion in Sales Expected for AbbVie Inc (ABBV) This Quarter
Wall Street brokerages expect AbbVie Inc (NYSE:ABBV) to report sales of $8.38 billion for the current fiscal quarter, Zacks Investment Research ...
Nyse NewsToday (press release)
Four Top Stock Picks For 2019: AbbVie, IBM, McCormick And ...
Every year for over three decades, MoneyShow.com has surveyed the nation's leading newsletter advisors asking for their favorite stocks for ...
Nyse Nasdaq News (press release)
More Encouraged After Recent Development? – Range Resources ...
AbbVie Inc. (NYSE:ABBV) experienced a gain of 0.06% from the closing price in the previous trading day. That boost the price to $85.55 per ...
Money Making News (press release)
Investors Buy Shares of AbbVie (ABBV) on Weakness
Traders purchased shares of AbbVie Inc (NYSE:ABBV) on weakness during trading hours on Monday. $172.53 million flowed into the stock on ...
Forbes - 6 hours ago
Is AbbVie (ABBV) a Great Value Stock Right Now?
One company value investors might notice is AbbVie (ABBV). ABBV is currently sporting a Zacks Rank of #2 (Buy) and an A for Value.
Financial Mercury - 8 hours ago
Becoming More Capital Intensive? Philip Morris International Inc ...
Philip Morris International Inc. (PM), AbbVie Inc. (ABBV) ... The current market cap of AbbVie Inc. is valued at $128.53B. The value there would ...
Fairfield Current - 1 day ago
AbbVie Inc. (ABBV)- Stock Sparks Rallying on Rosy Data
AbbVie Inc. (NYSE:ABBV) traded under umbrella of Healthcare sector, apart from individual factors many macro and micro factors also affects ...


Back